Verzenio results

[amitgarg27]

Plz share results of verzenio if any body taking if palbace fails

[ReikoM]

Hi there,

I just started taking Vernezio -- Dec. 26, 2019 - so too early to tell. I had problems with low white cell counts with Ibrance so now dealing with side effects of Vernezio (diarrhea!)

How are you doing?

Judy

[AuntyJane in reply to ReikoM]

It may be too early to know yet but I would be interested if your count is higher on Verzenio vs Ibrance? I am also struggling with low count on Ibrance (completed 4 rounds) despite lowering the dose. I thought Verzenio also affects count in addition to diarrhea as main side effects?

[ReikoM in reply to AuntyJane]

Just got the results of blood draw and my neutrophil count is okay to continue with Vernezio at the current (highest) dosage. Still dealing with bathroom issues though.

Wondering when that will go away!?

[Bestbird]

Based upon studies, it appears that Verzenio can be effective in patients experiencing prior failure on a CDK4/6 inhibitor.

Below from my book, "The Insider's Guide to Metastatic Breast Cancer," is a summary of relevant findings. To learn more about the book, which is also available as a complimentary .pdf please visit: insidersguidembc.com/about

Taking Verzenio after Prior Failure on Ibrance or Kisqali:

Although Ibrance, Kisqali and Verzenio are CDK4/6 inhibitors, Verzenio works somewhat differently. In an effort to determine whether Verzenio might be effective in patients previously treated with Ibrance, a SABCS 2019 poster by the Moffitt Cancer Center depicted study results of 28 heavily pre-treated hormone receptor positive, HER2 negative MBC patients who had previously progressed on Ibrance with endocrine therapy and had subsequently taken Verzenio (either as monotherapy or in combination with endocrine therapy). Of these patients, 23 (82.1%) had visceral involvement and 9 (32.1%) had brain metastases. These patients had received a mean of 5.4 prior lines of therapy, including chemotherapy. A total of seven (25%) patients had durable response to Verzenio. Of those patients 3 had a longer Progression Free Survival (PFS) compared with their prior PFS on Ibrance. Of the patients with durable response, 5 had available genomic profiling: 2 (28.5%) patients had an ESR1 mutation and 3 (42.8%) had PIK3CA mutations. It was concluded that age, duration of previous Ibrance-based therapy, number of prior therapies, presence of visceral or brain metastatic disease, number of mutations, and presence of ESR1 or PIK3CA mutations did not affect PFS on Verzenio-based therapy.

Another study evaluated clinical outcomes in patients with HR+/HER2- MBC who received Verzenio after progressing on either Ibrance or Kisqali in combination with endocrine therapy. Although 20 (34%) of the patients on Verzenio had disease progression in less than 3 months, 21 patients (36%) had a treatment response duration exceeding 6 months - including 10 patients who remained on treatment at interim analysis (range 181-413 days). The median PFS on Verzenio following a prior CDK4/6 inhibitor was 5.8 months. (Interestingly, a preliminary analysis of circulating free DNA revealed RB1 and FGFR1 alterations in patients who exhibited progressive disease). From: meetinglibrary.asco.org/rec...